Delforge ML - Search Results

1

In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine.

Delforge ML, Liesnard C, Debaisieux L, Tchetcheroff M, Farber CM, Van Vooren JP. Delforge ML, et al. AIDS. 1995 Jan;9(1):89-90. AIDS. 1995. PMID: 7893446 No abstract available.

2

Importance of method in the determination of syncytium-inducing phenotype of human immunodeficiency virus type 1 clinical isolates.

Liesnard C, Delforge ML, Tchetcheroff M, De Maertelaer V, Farber CM, Van Vooren JP. Liesnard C, et al. Among authors: delforge ml. J Virol Methods. 1997 Mar;64(2):137-45. doi: 10.1016/s0166-0934(96)02152-0. J Virol Methods. 1997. PMID: 9079760

3

Delayed HIV primary infection diagnosis with a fourth-generation HIV assay.

Delforge ML, Dollé N, Hermans P, Liesnard C. Delforge ML, et al. AIDS. 2002 Jan 4;16(1):128-30. doi: 10.1097/00002030-200201040-00018. AIDS. 2002. PMID: 11741173 No abstract available.

4

Acute Sjögren-like syndrome as the first manifestation of a generalized CMV infection in a patient with AIDS.

Van Vooren JP, Farber CM, Daelemans P, Delforge ML, Liesnard C. Van Vooren JP, et al. Among authors: delforge ml. J Laryngol Otol. 1995 Nov;109(11):1113-4. doi: 10.1017/s0022215100132177. J Laryngol Otol. 1995. PMID: 8551135

5

Chemotherapy of acute myeloblastic leukemia in an HIV carrier.

Farber CM, Ferehans W, Capel P, Delforge ML, Liesnard C, van Vooren JP. Farber CM, et al. Among authors: delforge ml. Eur J Haematol. 1993 Sep;51(3):180. doi: 10.1111/j.1600-0609.1993.tb00624.x. Eur J Haematol. 1993. PMID: 8405336 No abstract available.

6

Nutritional status and antiprotease therapy.

Delforge ML, Farine S, Liesnard C, Gulbis B, De Maertelaer V, Clumeck N, Farber CM, Van Vooren JP. Delforge ML, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):393-4. doi: 10.1097/00042560-199808010-00015. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9704948 Clinical Trial. No abstract available.

7

Porphyria cutanea tarda in a human immunodeficiency virus-infected patient: treatment with N-acetyl-cysteine.

Binet H, Simonart T, Van Vooren JP, Heenen M, Liesnard C, Delforge ML, Farber CM, Parent D. Binet H, et al. Among authors: delforge ml. Int J Dermatol. 1998 Sep;37(9):718-9. doi: 10.1046/j.1365-4362.1998.00481.x. Int J Dermatol. 1998. PMID: 9762833 No abstract available.

8

Spontaneous apoptosis and highly active antiretroviral therapy (HAART).

Dieye TN, Van Vooren JP, Delforge ML, Liesnard C, Devleeschouwer M, Farber CM. Dieye TN, et al. Among authors: delforge ml. Biomed Pharmacother. 2000 Feb;54(1):16-20. doi: 10.1016/s0753-3322(00)88636-9. Biomed Pharmacother. 2000. PMID: 10721458 Clinical Trial.

9

Foscarnet activity on human immunodeficiency virus type 1 in the central nervous system.

Delforge ML, Farber CM, De Leener F, Caroyer JM, Liesnard C, Van Vooren JP. Delforge ML, et al. Clin Infect Dis. 1999 Apr;28(4):931. doi: 10.1086/517256. Clin Infect Dis. 1999. PMID: 10825078 No abstract available.

10

Autologous stem cell infusion for acute myeloblastic leukemia in an HIV-1 carrier.

Schneider E, Lambermont M, Van Vooren JP, Bastin G, Feremans W, Kentos A, Lemoine F, Liesnard C, Delforge ML, Crenier L, Capel P, Farber CM. Schneider E, et al. Among authors: delforge ml. Bone Marrow Transplant. 1997 Oct;20(7):611-2. doi: 10.1038/sj.bmt.1700930. Bone Marrow Transplant. 1997. PMID: 9337065

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

68 results

Search Page